Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.5K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.5K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

358
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
358
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.2K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

499
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
499
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.8K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.1K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative plasma-to-spatial proteomics reveals fibroblast-associated signatures in liver metastatic breast cancer.

Cancer cell international·2026
Same author

Promise and pragmatism of AI in global-scale digital pathology: pan-cancer approaches for clinical practice.

Journal of clinical pathology·2026
Same author

Aberrant and Ectopic Cell Populations in Restrictive Allograft Syndrome after Lung Transplantation.

The European respiratory journal·2026
Same author

Alveolar macrophage activation and polarization signatures in stable lung transplant recipients and chronic lung allograft dysfunction.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Type 3 innate lymphoid cells dominate the ILC compartment in endstage lung disease.

Frontiers in immunology·2026
Same author

Peripartum-Associated Heart Failure Develops Independently of RHOT Proteins.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Oct 30, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

476

Pulmonary Fibroelastotic Remodelling Revisited.

Peter Braubach1,2, Christopher Werlein1,2, Stijn E Verleden3,4,5

  • 1Institute for Pathology, Hannover Medical School, 30625 Hannover, Germany.

Cells
|July 2, 2021
PubMed
Summary

Pulmonary fibroelastotic remodelling, a lung disease pattern, lacks clear terminology. This study defines its histological criteria and clinical variants for better patient stratification and outcome prediction.

Keywords:
alveolar fibroelastosisinterstitial fibrosislung

More Related Videos

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

494
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.1K

Related Experiment Videos

Last Updated: Oct 30, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

476
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
03:38

Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models

Published on: June 20, 2025

494
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.1K

Area of Science:

  • Pulmonary Pathology
  • Histomorphology
  • Disease Classification

Background:

  • Pulmonary fibroelastotic remodelling is observed across diverse diseases with varied prognoses.
  • Current terminology is insufficient to distinguish histomorphological and clinical entities.
  • Lack of standardized criteria hinders accurate patient stratification and outcome prediction.

Purpose of the Study:

  • To describe the spectrum of fibroelastotic changes in the lungs.
  • To establish stringent histological criteria for identifying these changes.
  • To clarify terminology and distinguish clinically relevant variants of pulmonary fibroelastotic remodelling.

Main Methods:

  • Retrospective analysis of pulmonary specimens with fibroelastotic remodelling from a lung transplant center.
  • Development of consensus-based definitions for specific fibroelastotic changes.
  • Systematic evaluation using a step-wise algorithm focusing on lesion morphology, distribution, and adjacent parenchyma.

Main Results:

  • Defined typical alveolar fibro-elastosis: collagenous effacement of alveolar spaces with hyper-elastosis of alveolar walls.
  • Identified this pattern in various conditions including idiopathic pleuroparenchymal fibro-elastosis, interstitial lung disease, post-transplant, autoimmune diseases, and radiation/chemotherapy.
  • Discovered novel in-transit and activity stages of fibroelastotic remodelling.

Conclusions:

  • Presents a comprehensive definition of fibroelastotic remodelling, its distribution, and clinical associations.
  • Provides a foundation for precise patient stratification.
  • Offers a basis for predicting patient outcomes in fibroelastotic lung diseases.